ATOMIC trial shows 86% three-year disease-free survival with atezolizumab combination

◆ TRIAL DATA

At a median follow-up of 40.9 months in the ATOMIC trial, the 3-year disease-free survival rate was 86.3% in patients receiving atezolizumab plus mFOLFOX6 compared with 76.2% in those receiving chemotherapy alone. (Targeted Oncology)